TY - JOUR
T1 - Tumor-specific positron emission tomography imaging in patients
T2 - [ 18F] fluorodeoxyglucose and beyond
AU - Mankoff, David A.
AU - Eary, Janet F.
AU - Link, Jeanne M.
AU - Muzi, Mark
AU - Rajendran, Joseph G.
AU - Spence, Alexander M.
AU - Krohn, Kenneth A.
PY - 2007/6/15
Y1 - 2007/6/15
N2 - Biochemical and molecular imaging of cancer using positron emission tomography (PET) plays an increasing role in the care of cancer patients. Most clinical work to date uses the glucose analogue [18F] fluorodeoxyglucose (FDG) to detect accelerated and aberrant glycolysis present in most tumors. Although clinical FDG PET has been used largely to detect and localize cancer, more detailed studies have yielded biological insights and showed the utility of FDG as a prognostic marker and as a tool for therapeutic response evaluation. As cancer therapy becomes more targeted and individualized, it is likely that PET radiopharmaceuticals other than FDG, aimed at more specific aspects of cancer biology, will also play a role in guiding cancer therapy. Clinical trials designed to test and validate new PET agents will need to incorporate rigorous quantitative image analysis and adapt to the evolving use of imaging as a biomarker and will need to incorporate cancer outcomes, such as survival into study design.
AB - Biochemical and molecular imaging of cancer using positron emission tomography (PET) plays an increasing role in the care of cancer patients. Most clinical work to date uses the glucose analogue [18F] fluorodeoxyglucose (FDG) to detect accelerated and aberrant glycolysis present in most tumors. Although clinical FDG PET has been used largely to detect and localize cancer, more detailed studies have yielded biological insights and showed the utility of FDG as a prognostic marker and as a tool for therapeutic response evaluation. As cancer therapy becomes more targeted and individualized, it is likely that PET radiopharmaceuticals other than FDG, aimed at more specific aspects of cancer biology, will also play a role in guiding cancer therapy. Clinical trials designed to test and validate new PET agents will need to incorporate rigorous quantitative image analysis and adapt to the evolving use of imaging as a biomarker and will need to incorporate cancer outcomes, such as survival into study design.
UR - http://www.scopus.com/inward/record.url?scp=34250712408&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250712408&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-07-0074
DO - 10.1158/1078-0432.CCR-07-0074
M3 - Review article
C2 - 17575208
AN - SCOPUS:34250712408
SN - 1078-0432
VL - 13
SP - 3460
EP - 3469
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 12
ER -